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ABSTRACT
Introduction: The objectives of this study were
to (a) assess the factors associated with weight
gain in a population of type 2 diabetes patients
escalating from metformin (M) to M?
sulfonylurea (M ? S) and (b) evaluate whether
healthcare resource utilization associated with
being overweight or obese is underestimated in
typical health economic evaluations.
Methods: The study was a retrospective cohort
study using UK Clinical Practice Research
Datalink linked to Hospital Episode Statistics
(CPRD/HES) data. The association between
baseline phenotypic factors and weight gain
was assessed using logistic regression.
Hospitalization incidence rates per 1000
person-years for major diabetes-related
complications according to body mass index
(BMI) at baseline were estimated from the data
(observed) and compared to those obtained
from a validated diabetes model (predicted).
Results: 11,071 patients were included in the
analysis; approximately 40% gained weight in
the first year following escalation to M ? S.
Baseline age, HbA1c and gender were found to
be predictors of weight gain [odds ratios 0.99
(1-year increment), 1.11 (1% increment) and
0.81 (female vs male), respectively, p\0.001].
Observed vs predicted incidence rates of
hospitalization were 265 vs 13 (normal), 297
vs 31 (overweight), 223 vs 50 (obese) and 378 vs
41 (severe obese).
Conclusion: This analysis suggests there are
identifiable patient characteristics predictive of
weight gain that may be informative to clinical
and economic decision making in the context
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of patients escalating from M to an M ? S
regimen. Hospital admissions in people with
type 2 diabetes were generally under-predicted.
A particular focus of future research should be
the need for diabetes models to make the
likelihood of experiencing an event
conditional on BMI.
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INTRODUCTION
The global prevalence of diabetes as of 2013 is
estimated at 382 million, accounting for 11%
(548 billion US dollars) of the total global
healthcare spend [1]. By 2035, diabetes
prevalence is expected to rise by 55% to 592
million and cost the global economy 627 billion
US dollars [1]. The majority of the cost
associated with type 2 diabetes is related to
the management of diabetes-related
macrovascular and microvascular
complications, such as cerebrovascular and
cardiovascular (CV) disease and diabetic
retinopathy, nephropathy and neuropathy [2].
There is an increasing amount of
epidemiological evidence relating body mass
index (BMI) to increased risk of CV disease and
all-causemortality (ACM) in patients with type 2
diabetes [3, 4]. Importantly, CV and mortality
risk equations typically incorporate the effects of
elevated BMI indirectly via the inter-relationship
between modifiable CV risk factors (such as
cholesterol and systolic blood pressure) and
BMI; this approach may underestimate the true
morbidity and mortality risk. Consequently, the
resource utilization associated with obesity in
patients with type 2 diabetes may also be
underestimated.
While the importance of avoiding
complications that decrease quality of life and
consume healthcare resources in people with
type 2 diabetes is well understood, the
relationship between patient phenotype and
resource utilization is less well researched. A
recent study by Balkau and colleagues assessed
the factors associated with weight gain in type 2
diabetes patients starting insulin [5]: high
baseline glycated hemoglobin (HbA1c), insulin
dose requirements and lower baseline BMI were
all associated with weight gain. In a separate
study, van Dieren and colleagues evaluated the
relationship between baseline profiles and
weight change among participants in the
ADVANCE diabetes trial (ClinicalTrials.gov
identifier, #NCT00145925) [6]. They found
that baseline factors associated with weight
gain were younger age, higher HbA1c,
Caucasian ethnicity and number of
glucose-lowering medications. These studies
illustrate that the identification of phenotypic
characteristics that are predictive of weight gain
at the time of treatment initiation or escalation
may help to develop strategies for avoidance of
weight gain [5], and any downstream adverse
patient outcomes and excess resource
utilization associated with weight gain, among
type 2 diabetes patients. Moreover, the accurate
prediction of the health and resource
consequences associated with the management
of type 2 diabetes is crucial to inform decision
making in healthcare.
With this in mind, the objectives of this
study were to (a) assess the factors associated
with weight gain in a population of type 2
diabetes patients escalating to the most
common dual oral therapy regimen and
(b) evaluate whether healthcare resource
utilization associated with being overweight or
obese is underestimated in typical health
economic evaluations in type 2 diabetes.
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METHODS
Data
Consistent with current consensus guidelines
on the management of hyperglycemia in
patients with type 2 diabetes, metformin
(M) augmented with a sulfonylurea (S) (M ? S)
is the predominant second-line oral diabetes
therapy in clinical practice [7]. The addition of S
to M is known to be associated with increased
weight gain [7]. Hence, as a population, this
cohort provides a potentially interesting case
study to assess the relationship between BMI
and healthcare resource utilization.
A retrospective cohort study of linked
primary (Clinical Practice Research Datalink,
CPRD) and secondary (Hospital Episode
Statistics, HES) data informed (a) the baseline
profiles for model initialization, (b) baseline
patient phenotypic factors predictive of weight
gain, and (c) an analysis of observed versus
predicted healthcare resource utilization
associated with increasing levels of BMI.
The study cohort consisted of all type 2
diabetes patients with a diagnosis code for
diabetes (READ/OXMIS code: C10?) between
01/01/2000 and 31/12/2011 in CPRD who
initiated treatment with M ? S. M ? S
combination therapy was defined as ‘‘a
prescription record for a combination product’’
or ‘‘concomitant use of M or S within 30 days’’.
Index date was defined as the date of addition of
S to M. The following inclusion criteria were
applied to obtain the study cohort (Fig. 1):
patients escalating from M monotherapy (to
minimize impact of indication bias), to ensure
that the beginning of combination therapy was
captured accurately (patients were required to
have had at least 12 months on M
monotherapy). Patients were required to have
at least 3 months’ treatment exposure to M ? S
in the post-index period (to minimize bias due
to therapy failure). The following exclusion
criteria were applied: a prescription for any
blood glucose-lowering therapy (other than M)
prior to the index date. Patients with a diagnosis
of malignant disease at any time point prior to
the index date, or during the follow-up period.
Data were extracted in quarterly (3-monthly)
time periods for the observational period; a
12-month pre-index period was defined for all
patients. Data are longitudinal in nature
(repeated observations of the same variables
and units over periods of time); quarterly
measurements were based on the last available
record for each study variable. Patient follow-up
was restricted to time on M ? S dual therapy.
Data were extracted based on READ codes
and CPRD/HES data files describing patient
characteristics: age, sex, smoking status,
weight, HbA1c, cholesterol, observed duration
of diabetes, in addition to medication use and
history of complications (defined in Table 1).
Resource utilization data were extracted
describing hospitalization and length of stay
(LOS).
Studies using CPRD data are covered by
ethics approval granted by the Trent
Multicenter Research Ethics Committee. This
study was granted CPRD Independent Scientific
Advisory Committee approval (ISAC protocol
number 13-191). This article does not contain
any new studies with human or animal subjects
performed by any of the authors.
Model
Assessing the ability of contemporary health
economic analyses in type 2 diabetes to capture
the resource utilization associated with
increasing levels of BMI was undertaken using
the IMS CORE Diabetes Model (CDM) [8]. This
model has been extensively validated and
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currently has 87 peer-reviewed publications,
predominantly related to cost-effectiveness
applications in both type 1 and type 2
diabetes. The model has previously been
described in detail [8]. In brief, the model is a
fixed-time increment (annual) stochastic
simulation using time-, state- and
patient-dependent characteristics to model the
likelihood of type 2 diabetes-related clinical
events occurring. Monte Carlo simulations are
performed at the individual patient level using
tracker variables to accommodate complex
interactions between individual complication
sub-models. The CDM simulates the following
diabetes-related microvascular and
macrovascular complications: angina,
myocardial infarction, congestive heart failure,
stroke, peripheral vascular disease, diabetic
retinopathy, macular edema, cataract,
hypoglycemia, ketoacidosis, nephropathy and
end-stage renal disease, neuropathy, foot ulcer
and amputation, and cardiovascular and
non-specific mortality. The CDM incorporates
direct and indirect costs, adjusts for quality of
life and derives cost-effectiveness and
cost-utility estimates.
The model begins by establishing patients’
clinical and demographic characteristics, which
determines how patients progress through the
model. The current analysis using the CDM
focuses on the number of events
(hospitalizations) and mortality predicted by
the model over a 3-year period to facilitate a
comparison of observed (CPRD/HES) vs
predicted (CDM) hospitalizations and
mortality.
Fig. 1 Flow diagram of study cohort selection with inclusion/exclusion criteria. M ? S metformin ? sulfonylurea
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Statistical Analysis
Factors Associated with Weight Gain
The association between phenotypic factors at
baseline (therapy escalation from M to M ? S)
and weight gain (defined as [2 kg weight
change over 12 months following therapy
escalation) was assessed in logistic regression
analysis with 1 = weight gain and 0 otherwise.
Patients were required to have a valid










n5 871 n5 3461 n5 3662 n5 2913 n5 11,071a
Mean SD Mean SD Mean SD Mean SD Mean SD
Age (years) 65.84 12.61 62.65 11.16 60.35 10.81 57.10 10.67 60.74 11.41
Female (%) 41% – 32% – 38% – 49% – 39% –
Current smoker (%) 5% – 6% – 6% – 6% – 6%
Duration diabetes (years) 6.41 5.85 5.62 3.82 5.32 3.83 4.75 3.51 5.36 3.98
Weight (kg) 66.82 9.20 80.62 10.15 92.75 11.53 112.82 18.39 92.15 19.56
HbA1c
% 8.53 1.62 8.53 1.44 8.73 1.69 8.88 1.52 8.70 1.57
mmol/mol 70 70 72 74 72
HDL-C (mmol/L) 1.33 0.39 1.19 0.31 1.14 0.28 1.12 0.28 1.17 0.31
LDL-C (mmol/L) 2.29 0.82 2.27 0.80 2.30 0.86 2.34 0.81 2.30 0.83
BMI (kg/m2) 23.27 1.36 27.74 1.37 32.25 1.41 40.03 5.02 32.16 6.12
Prior complications (%) 32% – 30% – 29% – 25% – 28% –
Respiratory/cerebrovascular
complications (%)
8% – 7% – 6% – 7% – 7% –
Vascular complications (%) 25% – 25% – 25% – 20% – 24% –
History CAD 18% – 17% – 17% – 15% – 17% –
History CHF 3% – 3% – 2% – 3% – 3% –
History neuropathy 1% – 1% – 1% – 1% – 1% –
History stroke 4% – 3% – 3% – 2% – 3% –
History retinopathy 13% – 12% – 10% – 9% – 10% –
History nephropathy \1% – \1% – \1% – \1% – \1% –
Variable deﬁnitions: ‘Prior complications’ (pre-index history of CAD, CHF, neuropathy, stroke, retinopathy,
nephropathy),‘Respiratory/cerebrovascular complications’ (=asthma, chronic obstructive pulmonary disease,
cerebrovascular disease), ‘Vascular complications’ (=CAD, cerebrovascular disease, peripheral vascular disease,
microalbuminuria, chronic kidney disease, retinopathy). History refers to history in 12-months prior to index date
BMI body mass index, CAD coronary artery disease, CHF congestive heart failure, HbA1c hemoglobin A1c, HDL-C high
density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation
a Overall n: 10,907 patients had a BMI record at baseline
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measurement at baseline and 12 months to be
included in this analysis, which estimated the
probability of weight gain, adjusting for
relevant differences in patient characteristics at
baseline. Model selection was based on a
backwards general-specific methodology,
eliminating statistically insignificant
covariates, covariate transformations and
interaction terms at the 0.05 level of testing to
estimate baseline factors predictive of weight
gain.
Observed vs Predicted Hospital Admissions
The association between hospitalizations
(number of admissions and LOS) and weight
status was assessed using BMI as the weight
measurement. This was required to assess the
relationship between observed and predicted
hospitalizations, as the CDM uses BMI as a risk
factor in estimating the incidence of
complications. Patients were classified by their
BMI at baseline: normal (C18.5 and \25),
overweight (C25 and \30), obese (C30 and
\35), and severe obese (C35).
Observed admissions were compared to the
number of events (admissions) predicted by the
CDM over a 3-year period, based on the number
of patients, baseline demographics and risk
factor profile of the cohort. Analysis was
stratified by BMI at baseline. The
corresponding total and average LOS of
admissions from the CPRD data were
descriptively summarized.
The observed vs predicted analysis was based
on incidence rates to account for variable
patient follow-up. For hospitalizations, the risk
set was treated as discontinuous risk intervals
(i.e., patients were not at risk of a subsequent
hospitalization until they had completed the
first hospitalization): person-time was
calculated by excluding the duration of
hospitalizations from the risk set (i.e.,
follow-up is equal to the sum of the
person-time for each risk interval) [9].
Incidence rates of hospitalizations per 1000
person-years were calculated for each BMI
category at baseline as the ratio of total
number of hospitalizations (numerator) and
the total person-years (denominator),
multiplied by 1000. Incidence rates from the
CDM were obtained by dividing the predicted
number of events by patient follow-up time in
the model, multiplied by 1000.
Observed vs Predicted Mortality
A comparison between observed and predicted
ACM was undertaken based on Kaplan–Meier
survival probabilities estimated over a 9-year
period for the average patient escalating to
M ? S dual therapy. This comparison aims to
assess the predictive performance of the CDM as
part of a typical economic evaluation compared
to the observed data and provide a second
comparative analysis to contrast the analysis of
observed vs predicted hospital admissions.
Analyses were undertaken using R version
2.12.2 (The R Foundation).
RESULTS
Patient (Baseline) Phenotypic Profiles
A total of 11,071 patients met the study
inclusion/exclusion criteria. The cohort had a
mean age at baseline of 60.74 (SD = 11.41)
years, duration of type 2 diabetes of 5.36
(SD = 3.98) years, HbA1c of 8.70%
(72 mmol/mol) (SD = 1.57), weight of 92.15 kg
(SD = 19.56) and BMI of 32.16 kg/m2
(SD = 6.12) and were 39% female (Table 1).
There was an increase in baseline mean weight
and BMI for increasing BMI categories.
Compared to the normal category, the
overweight, obese and severe obese categories
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were associated with successively younger mean
age at baseline (65.84, 62.65, 60.35, and
57.10 years, respectively) and shorter mean
diabetes duration at baseline (6.41, 5.62, 5.32,
and 4.75 years, respectively). People in the
obese and severe obese categories had higher
mean baseline HbA1c than people in the
normal category (8.7 and 8.9 vs 8.5,
respectively).
Factors Predictive of Weight Gain
In the 12-month period following initiation of
M ? S, weight gain (1 = weight gain; 0
otherwise) was observed in 40.39% of patients
with a valid measurement at baseline and
12 months (n = 3139/7771) and was
significantly associated with baseline age
(OR = 0.99 for 1-year increase in age,
p\0.001), female gender (OR = 0.81,
p\0.001) and baseline HbA1c (OR = 1.11 for
1% increase in HbA1c, p\0.001) (Table 2).
Observed vs Predicted Hospital
Admissions
Over the 3-year follow-up period, across BMI
categories, the most to least common events
associated with hospitalizations in the observed
dataset (CPRD/HES) were ischemic heart disease
(33%), end-stage renal disease (21%), congestive
heart failure (20%), myocardial infarction
(14%), stroke (13%), amputation (\1%) and
blindness (0%). The observed incidence rates of
hospitalizations per 1000 person-years
associated with myocardial infarction, stroke,
ischemic heart disease, congestive heart failure,
amputation, blindness and end-stage renal
disease were 265, 297, 223 and 378 for
normal, overweight, obese and severe obese
BMI categories, respectively. The predicted
(CDM) incidence rates of hospitalizations per
1000 person-years associated with the same
complications were 13, 31, 50 and 41 for
normal, overweight, obese and severe obese
BMI categories, respectively. These data are
presented in Fig. 2, which illustrates the
observed minus predicted incidence rates were
252, 266, 173 and 337 per 1000 person-years for
the increasing BMI categories. Thus, the CDM
generally under-predicted the incidence of
hospital admissions across event types, except
for amputation and blindness, where the model
slightly over-predicted incident rates compared
to the observed data. Overall, the difference
between observed and predicted events was
driven by end-stage renal disease, ischemic
heart disease, and congestive heart failure
hospitalizations, which in absolute terms
accounted for 74% of the observed versus
predicted difference (27%, 26%, 21%
respectively).
The total LOS associated with the observed
(CPRD/HES) 96 hospital admissions in the
normal BMI category was 1142 days (mean
LOS = 15.0); for the overweight category, total
LOS was 4691 (419 admissions, mean
LOS = 11.2); for the obese category, total LOS
was 4791 (477 admissions, mean LOS = 10.0);
and for the severe obese category, total LOS was
3896 (717 admissions, mean LOS = 5.4).
Observed vs Predicted Mortality
Figure 3 contrasts observed survival from
CPRD/HES with predicted survival from the
CDM. At year 9, Kaplan–Meier survival
probability was 0.780 (95% CI 0.761–0.800)
compared to 0.749 (0.730–0.769). Although
the point estimate of the survival probability
from the CDM fell below the confidence
interval from the observed data, visual
inspection of Fig. 3 indicates a reasonable fit
to overall mortality.
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DISCUSSION
Study Objectives and Results
The aim of this study was to identify baseline
patient characteristics predictive of weight gain
and to assess whether typical health economic
evaluations capture the excess secondary care
healthcare resource utilization associated with
weight gain using linked primary and secondary
care data from the UK in people with a
diagnosis of type 2 diabetes escalating from M
to M ? S combination therapy.
Regarding the first objective of this study,
understanding the baseline factors predictive of
weight gain is important as it may help to
inform both clinical and economic decision
making. Where there are identifiable patient
characteristics predictive of weight gain, these
could help guide treatment decisions and define
management strategies, potentially improving
patient health outcomes and directing
healthcare resources to efficient uses. We
found that there are identifiable phenotypic
characteristics predictive of weight gain in the
M ? S cohort. Around 40% of patients gained
Table 2 Baseline factors predictive of weight gain
Odds Ratio 95% CI (lower) 95% CI (upper) Pr (>IzI)
Age (years) 0.99 0.98 0.99 \0.001
Gender (female vs male) 0.81 0.71 0.91 \0.001
HbA1c (%) 1.11 1.07 1.16 \0.001
CI conﬁdence interval, HbA1c hemoglobin A1c, Pr ([IzI) probability being greater than z and less than -z, where z is the
value of the standard normal distribution
Fig. 2 Comparison of observed incidence rate of hospital
admissions stratiﬁed by BMI for myocardial infarction,
stroke, ischemic heart disease, congestive heart failure,
amputation, blindness and end-stage renal disease with
CPRD/HES compared to the incidence rate predicted by
the CDM. BMI body mass index, CDM IMS CORE
Diabetes Model, CPRD/HES Clinical Practice Research
Datalink/Hospital Episode Statistics
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weight in the first year following escalation to
M ? S; gender, baseline age and baseline HbA1c
were found to be predictors. These factors are
consistent with the phenotypic factors
identified in studies of patients starting insulin
therapy [5] and in patients assigned to receive
conventional vs intensive management [10].
The results of this study may usefully inform on
type 2 diabetes management strategies and
investment of healthcare resources; given that
M ? S is the most common second-line
therapeutic regimen.
Regarding the second objective of this study,
when initialized to the baseline profiles
observed in the CPRD population treated with
M ? S, the CDM generally under-predicted
hospital admissions associated with the most
common complications in people with type 2
diabetes. There was an increasing discrepancy
between the CPRD observations and CDM
predictions for increasing levels of BMI. For
instance, the CDM predicted 265 fewer
admissions in the normal BMI category,
compared to 337 fewer predicted admissions
for the severe obese category, per 1000
person-years. This type of discrepancy may
have implications for economic modeling used
to inform healthcare decisions and clinical
decision making where both patient
phenotype and the results of economic
modeling can impact treatment decisions.
Diabetes Modeling
It was not the objective of this study to cast
doubt over the predictive validity of the CDM.
The model has been subject to a number of
validation exercises and routinely participates
in the Mount Hood challenge meetings, a
forum for diabetes modelers to compare and
Fig. 3 Comparison of Kaplan–Meier observed survival
plot for all-cause mortality (with 95% upper and lower
conﬁdence intervals) compared to output from the CDM.
CDM IMS CORE Diabetes Model, CPRD Clinical
Practice Research Datalink, LCL lower conﬁdence limit,
M ? S metformin ? sulfonylurea, UCL upper conﬁdence
limit
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contrast model results over a series of
standardized validation exercises [11, 12];
furthermore, the CDM has been shown to
capture the incidence of long-term
diabetes-related complications with a high
degree of accuracy [13]. Our concern rests with
whether the risk equations typically used in
diabetes models are failing to adequately
capture the multiple comorbidities that can
occur. The CDM model, as with most published
contemporary type 2 diabetes models, is based
on the United Kingdom Prospective Diabetes
Study (UKPDS) 68 risk equations [14]. BMI
features in only one of several risk prediction
equations: coronary heart failure. Modeling
under-predicted the incidence of myocardial
infarction, stroke, ischemic heart disease,
congestive heart failure and end-stage renal
disease compared to the observed data. The
results of this analysis suggest that BMI may
have a much larger role to play in determining
the risk of diabetes complications, as this
analysis suggests higher BMI levels were
associated with more hospitalizations. While
this study reports an apparent trend of reduced
LOS for increasing BMI, overall the findings of
this research suggest that secondary healthcare
resource utilization is higher for increasing BMI,
as reflected by more frequent admission. The
recent publication of the updated UKPDS 82 risk
equations [15], where BMI is a risk factor for a
larger number of diabetes-related
complications, further emphasizes the
importance of accurately modeling the
relationship between complication incidence
as a function of increasing BMI.
A consequence of these findings is that
long-term projections obtained from diabetes
models may not adequately reflect the benefit
of improved risk factor profiles. In particular,
the value of diabetes management strategies
that minimize weight gain may be
underestimated as a result. It is noteworthy
that the UKPDS equations are most commonly
criticized for potentially over-predicting
complication rates [10, 16]; this study suggests
they may significantly under-predict total
burden associated with diabetes-related
complications.
Diabetes models are central to informing
decisions around product reimbursement and
hence the treatment alternatives available to
clinicians and ultimately patients. In this
context, and based on the analysis of this
patient cohort, there is a case for further
investigation around how diabetes models
characterize the relationship between weight
and hospital admissions; a relationship
complicated by many confounding factors
such as comorbidities and disease
management. Two immediate areas of
investigation are how models address the
probability of hospitalization as a function of
changing BMI and, once hospitalized, the
assignment of cost to event. Current models
almost exclusively apply an average cost to each
type of diabetes complication. This approach
may be appropriate where there are no expected
differences in hospital LOS as a function of BMI
or misleading where LOS is a function of
changes in BMI. The current analysis more
strongly highlights the need for diabetes
models to make the likelihood of experiencing
an event conditional on BMI.
Study Limitations
The findings of this study are set against the
following limitations. First, not all relevant
confounding factors are captured in the CPRD/
HES databases. Thus, predicting association
between BMI and resource use, and baseline
factors predictive of weight gain is limited by
the coverage and completeness of the data,
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though the databases contain significant detail
on the patient characteristics most relevant to
this analysis. There may be under-reporting for
certain variables within the dataset; for
example, the prevalence of congestive heart
failure and nephropathy appears low. However,
given the age distribution of the cohort,
congestive heart failure prevalence around 3%
is not surprising since these patients are
probably not that far into their disease course
as they have been users of M (first line) and have
only just needed augmentation. Nephropathy
can take several years to manifest, which may
account for the apparently low rate observed;
although other studies suggest a significant
proportion of type 2 diabetes with a relatively
short disease duration would have had
nephropathy [17].
Second, by nature, observational studies of
this kind will be subject to ‘confounding by
indication’, such that any observed patterns
within the data are a function of patient
phenotype, and patient phenotype is the
reason for prescription of a specific therapy.
Restricting analysis to only M ? S patients
minimizes this potential confounder. The
inferences that can be made from the current
analysis of observed versus predicted hospital
admissions are indirectly strengthened by the
analysis of observed versus predicted ACM,
where estimates from CPRD and the CDM
generally predicted the same survival
probabilities over a 9-year period. Observed
versus predicted survival estimates may have
been closer, possibly due to the nature of
mortality as an endpoint in that it may be
better recorded in CPRD compared to events,
and/or the estimation of mortality via UKPDS
equations is more accurate; however, the
precise reason cannot be determined from
this data.
Finally, the CDM was used to evaluate the
expected occurrence of events based on risk
factor profiles observed in routine clinical
practice; these estimates were compared
against observed event rates. Statistical
adjustment of the data, accounting for the
influence of patient characteristics at baseline
and over time on the observed relationship
between hospitalization rates and BMI, was not
undertaken given that the primary aim of this
study was to assess the relationship between
observed vs predicted hospital admissions in the
context of economic evaluation. Thus, reported
incidence rates should be interpreted as
unadjusted estimates from an epidemiological
perspective.
CONCLUSION
This real-world observational analysis suggests
that there are identifiable patient characteristics
that are predictive of weight gain, which may be
informative to clinical and economic decision
making among the context of patients
escalating to an M ? S regimen.
Increased BMI was associated with an
increased rate of hospitalization, although
average LOS was observed to decrease with
increasing BMI. Overall, these findings suggest
that there may be an important relationship
between increasing BMI and hospitalization
that may not be adequately captured in widely
used vascular risk equations such as UKPDS.
Consequently, the value of diabetes
management strategies that minimize weight
gain may be underestimated. Models used to
predict health outcomes and characterize the
value of competing interventions in type 2
diabetes should be investigated in light of these
findings. A particular focus of future research
should be the need for diabetes models to make
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the likelihood of experiencing an event
conditional on BMI.
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